ArticleSurgical oncology insight2025
Impact of a technology enhanced breast multidisciplinary cancer conference.
Article in Surgical oncology insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Multidisciplinary cancer conferences (MCCs) are the standard approach for managing complex breast cases and technology can facilitate these meetings. The objectives of this study were to assess the impact of technology on quality of patient information, case deliberation, and various outcome measures. Methods: We conducted a prospective study from September 2020 to February 2022, before and after implementation of a digital platform for tumor boards. We collected observational and survey data to assess its impact on quality of breast MCC case presentation and discussion. We also reviewed medical records to compare outcomes including rate of change in care plans, compliance of care plans with national guidelines, concordance of treatment received with MCC recommendations and time from MCC presentation to treatment. Comparisons were made using the Mann-Whitney U and Fisher's exact tests. Results: There were 39 pre- and 47 post-digital platform patient cases. We found that implementation of technology led to an improvement in the quality of the MCCs (median composite scores: 56.9 vs 68.4; p < 0.001). Specific components significantly improved included case history, reason for presentation, radiology and pathology presentations, and medical oncology contribution to case discussions (mean scores: 3.4 vs 3.9, 3.3 vs 3.9, 2.7 vs 4.1, 3.1 vs 4.2; (p < 0.001), & 3.7 vs 4.1; p = 0.05). There was also an improvement in the frequency of arrival at consensus (71.8 % vs 95.7 %; p < 0.012). Conclusion: A tumor board digital platform was shown to improve the quality of presented patient information, physician engagement, and arrival at consensus at multidisciplinary breast cancer conferences. Synopsis: Multidisciplinary cancer conferences (MCCs) play an important role in breast cancer management. We evaluated the impact of a tumor board-specific technology on the quality of breast MCCs and subsequent care. We found that technology improved the quality of information presented and physician engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.